PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Industry Poised for Rapid Expansion, Projected to Hit $89.62 Billion by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Large Is the PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Expected to Be in 2029?
Recent years have seen a swift expansion of the PD-1 and PDL1 inhibitors or immune checkpoint inhibitors market. The market is set to surge from $45.8 billion in 2024 to $52.49 billion in 2025, registering a compound annual growth rate (CAGR) of 14.6%. This remarkable growth during the historic period can be credited to breakthroughs in immunotherapy, heightened clinical success and approvals, a rising incidence of cancer, a paradigm shift in cancer treatment, and increasing collaboration and research investments.
The market for PD-1 and PDL1 inhibitors/ immune checkpoint inhibitors is projected to experience substantial expansion in the upcoming years. The anticipated valuation of this market is “$89.62 billion in 2029, with an accelerated compound annual growth rate (CAGR) of 14.3%. Several factors contributing to the anticipated surge in the forecast period are extended applications, research in biomarkers and personalized medicine, clinical trials, and research partnerships, as well as development in global healthcare infrastructure. Key trends for the forecast period include emphasis on patient access and affordability, international collaborations in clinical trials, combinations of immunotherapy, patient-focused strategies, along with updated regulations and approvals.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10788&type=smp
What Are The Contributors To Demand In The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market?
The escalation of cancer incidences is anticipated to boost the progression of the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market. Cancer manifests when certain cells grow uncontrollably and disseminate to different body regions. PD-1 and PD-L1 inhibitors are utilized to combat cancer by tapping into the body’s immune resources to battle cancer cells. Consequently, the surge in cancer incidences underpins the growth of the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market. As an example, the European Union Science Hub, a joint research center of the European Commission located in Belgium, indicated in October 2023 that there had been a 2.3% rise in new cancer incidences in the two years preceding 2022, totaling 2.74 million. Similarly, there was a 2.4% increase in cancer-related fatalities over the preceding two years. Thus, the increasing prevalence of cancer is set to stimulate the growth of the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market.
The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market covered in this report is segmented –
1) By Product: Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab
2) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies
3) By Application: Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Colorectal Cancer, Other Applications
4) By End-Users : Hospitals, Specialty Clinics, Academic and Research Institutions
Subsegments:
1) By Nivolumab: Monotherapy, Combination Therapy
2) By Pembrolizumab: Monotherapy, Combination Therapy
3) By Atezolizumab: Monotherapy, Combination Therapy
4) By Avelumab: Monotherapy, Combination Therapy
5) By Durvalumab: Monotherapy, Combination Therapy
Which Trends Are Redefining The Future Landscape Of The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Industry?
In the PD-1 and PDL1 Inhibitors/ immune checkpoint inhibitors market, product innovation is becoming increasingly popular as a leading trend. To consolidate their foothold in the market, major market players are focusing on the development of innovative products. For example, US-based pharmaceutical company Bristol-Myers Squibb received FDA approval in March 2022 for Opdualag, a fixed-dose combination of nivolumab (Opdivo) and relatlimab, a LAG-3 inhibitor. This made Opdualag the first LAG-3 inhibitor to gain approval from the FDA to treat metastatic melanoma patients. The objective of combining nivolumab and relatlimab in Opdualag is to boost the immune response against cancer cells.
Regeneron Increases Its Global Reach in the PD-1 and PDL1 Inhibitor Market by Taking Over Full Control of Libtayo
In order to strengthen their positions, major companies in the PD-1 and PDL1 inhibitor/immune checkpoint inhibitor market, like Regeneron Pharmaceuticals, Inc., are opting for strategic investments. Regeneron secured exclusive rights to develop, market, and produce Libtayo (cemiplimab) globally by acquiring Sanofi’s equity in their joint venture on Libtayo. To gain sole control of Libtayo, Regeneron’s plan was to pay Sanofi $900 million, in addition to royalties and any subsequent milestone payments. In June 2022, for instance, Regeneron Pharmaceuticals, a US-based pharmaceutical company, invested $900 million in exclusive authority to develop, market, and manufacture Libtayo, a fully human monoclonal antibody that targets the PD-1 immunological checkpoint receptor on T cells. Developed using Regeneron’s patented VelocImmune technology, Libtayo has been approved by the FDA and regulatory authorities in over 24 countries for a cemiplimab-rwlc monotherapy treatment for certain patients with advanced non-small cell lung cancer (NSCLC), advanced cutaneous squamous cell carcinoma (CSCC), and advanced basal cell carcinoma (BCC). Recognized as a standard of care, Libtayo is the first PD-1 inhibitor used to treat approved non-melanoma skin cancers. Sanofi S.A., a French pharmaceutical and healthcare company, was the previous owner of this share in Libtayo.
Who Are The Top-Ranked Companies In The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Today?
Major companies operating in the PD-1 and PDL1 inhibitors/ immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck and Company, F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc., BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd., Akeso Inc., Alphamab Oncology, Eli Lilly and Company, Boehringer Ingelheim, Xencor Inc., Taiga Biotechnologies Inc., Jiangsu Alphamab Biopharmaceuticals Co. Ltd, Dr. Reddy’s Laboratories Ltd., Laekna Therapeutics, Genentech Inc., Tracon Pharmaceuticals Inc., Celgene, Hangzhou Sumgen Co. Ltd, Agenus Inc., BioNTech SE, Celldex Therapeutics Inc., CytomX Therapeutics Inc.
How Is PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Adoption Varying Across Different Regions And Sectors?
North America was the largest region in the PD-1 and PDL1 inhibitors market in 2024. The regions covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10788&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
